GROWTH STRATEGY: Pfizer’s CEO is looking to increase revenue and profit with small purchases, licensing deals and research partnerships, not another “mega-acquisition” like the ones that brought fast growth over the last decade. GROWTH DRIVERS: Ian Read says Pfizer has five key drugs that will drive near-term growth, from a blockbuster vaccine just approved for adults to drugs for rheumatoid arthritis and kidney cancer now awaiting approval. RE-SIZED RESEARCH: Pfizer has cut its budget by about $1 billion by eliminating its least-promising research projects.
